All Clinical Trials

Clinical Trial

Treatment Use of the CliniMACS® CD34 Reagent System to Prepare Cells for an Unlabeled Indication Using an HLA-Compatible Related or Unrelated Donor for Allogenic Transplant

  • Recruiting participants (Starts Sep. 29, 2014)
  • Not accepting healthy volunteers
  • UTSW Principal Investigator: TIFFANY R SIMMS-WALDRIP

summary

This is not considered research. We are requesting iRB approval forfor use of CliniMaCS CD34 Reagent System to obtain CD34+ cell-enriched population for hematopoietic reconstitution following a myeloblative preparative regimen without the need for additonal graft versus host disease (GVHD) prophylaxis.

objective

To process hematopoietic progenitor cells collected by apheresis (HPC, apheresis) from an related or unrelated donor to obtain CD34 enriched population for hematopoietic reconstitution following a myeloblative preparative regimen without the need for additional graft versus host disease (GVHD) prophylaxis.

eligibility

Not applicable as this is not a research study,

If you are interested in this clinical trial, please contact Gevel Jackson on the Children’s Health Research Team.Call 214-456-7194Email